Form 4: Privia Health Director Exercises, Sells Shares

Privia Health Group Director Matthew Shawn Morris exercised stock options and subsequently sold common stock totaling 24,338 shares in pre-planned transactions.

Summary

• Matthew Shawn Morris, a Director of Privia Health Group, Inc. (PRVA), engaged in transactions involving the company's common stock and stock options.
• On February 26, 2026, Morris exercised options to acquire 7,788 shares of common stock at an exercise price of $2.00 per share.
• Immediately following, on February 26, 2026, Morris sold these 7,788 shares of common stock at a weighted average price of $24.99 per share, with prices ranging from $24.95 to $25.13.
• On February 27, 2026, Morris exercised options to acquire an additional 16,550 shares of common stock at an exercise price of $2.00 per share.
• Subsequently, on February 27, 2026, Morris sold these 16,550 shares of common stock at a weighted average price of $25.00 per share, with prices ranging from $24.95 to $25.15.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Morris.
• Following these transactions, Morris directly beneficially owns 68,188 shares of common stock.
• Morris also indirectly beneficially owns 11,998 shares via a Trust and 12,487 shares via Emerald Family, LLC.
• The stock options exercised were fully vested and exercisable.
• After these transactions, Morris holds 3,692,314 unexercised stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, these transactions were pre-planned under a 10b5-1 plan, mitigating concerns about immediate insider sentiment.

Positives

• Director Morris realized a significant gain by exercising options at $2.00 and selling shares at approximately $25.00.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned activity rather than a reaction to new, non-public information.

Negatives

• The sale of 24,338 shares by a director could be interpreted by some investors as a reduction in direct equity exposure, although it is part of a pre-arranged plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common for executives and directors managing their personal equity holdings and do not necessarily reflect a change in the company's fundamental outlook or broader industry trends in healthcare services.

Related Party Transactions

• The transactions involve a director of Privia Health Group, Inc. selling company stock, which is inherently a related party transaction. However, the specific field usually refers to broader company dealings, which are not detailed here beyond the individual's transactions.

Stakeholder Impact

• Shareholders may observe a director reducing direct equity holdings, though the pre-planned nature of the sale under a 10b5-1 plan suggests it is for personal financial management rather than a reflection of company performance or outlook.

Key Dates

Recommendation

The transactions represent routine personal financial management by a director under a pre-established 10b5-1 plan, rather than a signal of changing company fundamentals. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, Stock Options, Share Sale, Director Transactions, Rule 10b5-1, Equity Sales, Beneficial Ownership